Bortezomib clinical trials
Also written Velcade, LDP 341 and MLN341.
Related medicines add 4 studies
Counted the way a researcher would: Bortezomib with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Bortezomib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Bortezomib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 13 May 2003 · VELCADE · NDA 021602 (FDA, Drugs@FDA)
- European Union
- 26 Apr 2004 · Velcade · EMEA/H/C/000539 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Brand
- Velcade
- 341
Studies by the year they started
643 studies that test it; most in 2006 (69)
| Year | Studies |
|---|---|
| 1999 | 2 |
| 2000 | 3 |
| 2001 | 18 |
| 2002 | 13 |
| 2003 | 20 |
| 2004 | 42 |
| 2005 | 63 |
| 2006 | 69 |
| 2007 | 40 |
| 2008 | 47 |
| 2009 | 40 |
| 2010 | 47 |
| 2011 | 28 |
| 2012 | 23 |
| 2013 | 29 |
| 2014 | 16 |
| 2015 | 16 |
| 2016 | 20 |
| 2017 | 14 |
| 2018 | 9 |
| 2019 | 15 |
| 2020 | 11 |
| 2021 | 13 |
| 2022 | 13 |
| 2023 | 11 |
| 2024 | 11 |
| 2025 | 2 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 83 · Other 568
National Cancer Institute (NCI) (70) · M.D. Anderson Cancer Center (26) · Millennium Pharmaceuticals, Inc. (24) · University of Arkansas (15) · Dana-Farber Cancer Institute (14) · Mayo Clinic (13) · Memorial Sloan Kettering Cancer Center (12) · Janssen Research & Development, LLC (8)
Often tested with
Tested in the same studies.
Dexamethasone (154) · Rituximab (60) · Lenalidomide (57) · Cyclophosphamide (56) · Doxorubicin (43) · Melphalan (30) · Thalidomide (27) · Daratumumab (25)
Related medicines
As reviewed, each with the page that says it.
- One of Proteasome inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 19 phase 3 studies under way
Bortezomib is the comparator. A study of two new drugs counts under both.
- 3Daratumumab · PETHEMA Foundation, Pfizer · next primary completion Oct 2030
- 2Teclistamab · Janssen Research & Development, LLC, University of Heidelberg Medical Center · next primary completion Feb 2031
- 2Belantamab mafodotin · GlaxoSmithKline
- 2Ramantamig · Janssen Research & Development, LLC · next primary completion Sep 2030
- 2Elranatamab · Pfizer · next primary completion Oct 2030
- 1Equecabtagene autoleucel · Nanjing IASO Biotechnology Co., Ltd. · next primary completion Aug 2027
- 1Talquetamab · Janssen Research & Development, LLC
- 1Pomalidomide · Janssen Research & Development, LLC
Reaching primary completion within a year · 15, 5 in phase 3
Studies that test Bortezomib, phase 3 first.
- Dec 2026Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)Phase 3 · University of Chicago
- Dec 2026Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)Phase 3 · Children's Cancer Group, China
- Apr 2027A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantPhase 3 · Sanofi
- Aug 2027Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma PatientsPhase 2/3 · University Hopsital Schleswig Holstein Campus Lübeck
- Sep 2027UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk MyelomaPhase 3 · University of Arkansas
- Dec 2026Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN DeletionPhase 2 · University of Utah
- Dec 2026A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple MyelomaPhase 2 · Massachusetts General Hospital
- Dec 2026Bortezomib, Pomalidomide, Dexamethasone for Systemic AL AmyloidosisPhase 2 · Jin Lu, MD
- Feb 2027A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)Phase 2 · Memorial Sloan Kettering Cancer Center
- Mar 2027Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary DiseasePhase 2 · Stichting European Myeloma Network
Studies
Open first, then newest update. How each study uses Bortezomib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 651
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT04566328Written as Bortezomib
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) AmyloidosisRecruitingPhase 2GlaxoSmithKlineNCT07224672Written as Bortezomib
- Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.RecruitingPhase 2Fondazione Italiana Linfomi - ETSNCT04915248Written as Bortezomib
- Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM PatientsRecruitingPhase 2Canadian Myeloma Research GroupNCT05272826Written as Bortezomib
- Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic LymphomaRecruitingPhase 1M.D. Anderson Cancer CenterNCT07513129Written as Bortezomib
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03136146Written as Bortezomib
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingPhase 2St. Jude Children's Research HospitalNCT06390319Written as Bortezomib
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Not yet recruitingPhase 2/3Children's Oncology GroupNCT07072585Written as Bortezomib
- Optimize First-line Treatment for AL Amyloidosis With t (11; 14)RecruitingNot applicableJin Lu, MDNCT06192979Written as Bortezomib
- A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)RecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06083922Written as Bortezomib
- Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple MyelomaNot yet recruitingPhase 2GlaxoSmithKlineNCT07614360Written as Bortezomib
- Acalabrutinib Maleate and Bortezomib for Patients With HLA AntibodiesNot yet recruitingPhase 3The First Affiliated Hospital of Soochow UniversityNCT07635511Written as bortezomib
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)RecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05736419Written as Bortezomib
- Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)RecruitingPhase 1/2Northwell HealthNCT05289167Written as Bortezomib
- A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic ImpairmentNot yet recruitingPhase 1GlaxoSmithKlineNCT07609706Written as Bortezomib
- Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL AmyloidosisRecruitingPhase 3SWOG Cancer Research NetworkNCT06022939Written as Bortezomib
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)RecruitingPhase 3Children's Cancer Group, ChinaNCT05681260Written as Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin
- International Study for Treatment of High Risk Childhood Relapsed ALL 2010RecruitingPhase 2Charite University, Berlin, GermanyNCT03590171Written as Bortezomib
- HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and BortezomibRecruitingPhase 2Henry Ford Health SystemNCT03850366Written as Bortezomib
- The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune ThrombocytopeniaRecruitingPhase 2Seoul National University HospitalNCT05599880Written as Bortezomib
See all 651 studies that test Bortezomib →
Given beside what is tested · 195 — Bortezomib is usual care or a partner of the new treatment
- To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Kite, A Gilead CompanyNCT07903506Written as Bortezomib
- Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney FailureRecruitingPhase 2Eastern Cooperative Oncology GroupNCT07085728Written as Bortezomib (VELCADE)
- TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIRecruitingPhase 1/2Tanja Andrea GruberNCT05848687Written as Bortezomib
- Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaRecruitingPhase 3PrECOG, LLC.NCT07285239Written as Bortezomib
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Bortezomib
- A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)RecruitingPhase 3Regeneron PharmaceuticalsNCT07222761Written as Bortezomib
- Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeRecruitingPhase 1Andrew Hantel, MDNCT07341867Written as Bortezomib
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingPhase 3CelgeneNCT05519085Written as Bortezomib
- A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.RecruitingPhase 2Karyopharm Therapeutics IncNCT04414475Written as Bortezomib
- Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple MyelomaRecruitingPhase 2Tata Memorial CentreNCT07891923Written as Bortezomib (BTZ)
- Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)RecruitingPhase 1/2Masonic Cancer Center, University of MinnesotaNCT07008638Written as Bortezomib
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaNot yet recruitingPhase 2/3Alliance for Clinical Trials in OncologyNCT07887984Written as Bortezomib
- A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Kite, A Gilead CompanyNCT07887672Written as Bortezomib
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM PatientsRecruitingPhase 3Intergroupe Francophone du MyelomeNCT06918002Written as Bortezomib (Velcade®)
- CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07652905Written as Bortezomib
- Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed MyelomaNot yet recruitingPhase 1/2Dana-Farber Cancer InstituteNCT07601100Written as Bortezomib
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)RecruitingPhase 2GlaxoSmithKlineNCT07227311Written as Bortezomib
- Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTRecruitingPhase 3AstraZenecaNCT07764978Written as Bortezomib
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingPhase 1/2Karyopharm Therapeutics IncNCT02343042Written as Bortezomib
- NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-IberdomideRecruitingPhase 3PETHEMA FoundationNCT05558319Written as Bortezomib
Showing 20 of 195.
As the comparator · 33 — what is tested is compared with Bortezomib
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131Not yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07933432Written as Bortezomib for Injection
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)RecruitingPhase 3PfizerNCT06152575Written as Bortezomib
- A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant EligibleNot yet recruitingPhase 3Janssen Research & Development, LLCNCT07903272Written as Bortezomib
- A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not PlannedRecruitingPhase 3Janssen Research & Development, LLCNCT07665450Written as Bortezomib
- Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain AmyloidosisNot yet recruitingPhase 3Regeneron PharmaceuticalsNCT07901725Written as Bortezomib
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingPhase 3PfizerNCT05623020Written as Bortezomib
- D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMMRecruitingPhase 3Dana-Farber Cancer InstituteNCT07624513Written as Bortezomib (B)
- A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)RecruitingPhase 3AstraZenecaNCT07391657Written as Bortezomib
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003RecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07623798Written as Bortezomib for Injection
- Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) AmyloidosisNot yet recruitingPhase 3AbbVieNCT07793422Written as Bortezomib
- GMMG-HD11/DSMM XXI/64007957MMY3010Not yet recruitingPhase 3University of Heidelberg Medical CenterNCT07671287Written as Bortezomib (B)
- Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentRecruitingPhase 3SWOG Cancer Research NetworkNCT05561387Written as Bortezomib
- Isa-VRD in TIE HRMMNot yet recruitingPhase 4Peking Union Medical College HospitalNCT07334535Written as Bortezomib, Lenalidomide, Dexamethasone
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingPhase 3Nanjing IASO Biotechnology Co., Ltd.NCT06464991Written as Bortezomib
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06208150Written as Bortezomib
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaActive, not recruitingPhase 3Kite, A Gilead CompanyNCT06413498Written as Bortezomib
- Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple MyelomaActive, not recruitingPhase 3GlaxoSmithKlineNCT04484623Written as Bortezomib
- All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple MyelomaActive, not recruitingPhase 3GlaxoSmithKlineNCT06956170Written as Bortezomib
- Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Active, not recruitingPhase 3CelgeneNCT04975997Written as Bortezomib
- Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple MyelomaCompletedPhase 3Stichting Hemato-Oncologie voor Volwassenen NederlandNCT01208766Written as Bortezomib, Melphalan, Prednisone (VMP)
Showing 20 of 33.
What changed recently
From the registry's own updates since Oct 18, 2026.
Stopped2
- Sorafenib and Bortezomib in Treating Patients With Advanced CancerTerminatedNov 12, 2026NCT00303797
- A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home EnvironmentTerminatedOct 28, 2026NCT04268199
Codes
What other systems call Bortezomib · ClinicalTrials.gg INT006569
- MeSH (NLM) D000069286BortezomibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 69G8BD63PPBORTEZOMIBConfirmed FDA, NLM, Wikidata
- RxNorm 358258Confirmed FDA, Wikidata
- Wikidata Q419319bortezomibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1851BortezomibOne source FDA
- DrugBank DB00188One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069286 | Bortezomib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 69G8BD63PP | BORTEZOMIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 358258 | — | Confirmed FDA, Wikidata |
| Wikidata | Q419319 | bortezomib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1851 | Bortezomib | One source FDA |
| DrugBank | DB00188 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.